高迁移率族蛋白B1在肺动脉高压中的作用  

Role of high-mobility group B1 in pulmonary arterial hypertension

作　　者：陈阳[1] 何庆[1] Chen Yang;He Qing(Department of Emergency,Clinical College of Southwest Jiao Tong University,the Third People's Hospital of Chengdu,Chengdu 610036,Sichuan,China)

机构地区：[1]西南交通大学临床医学院,成都市第三人民医院急诊科,成都610036

出　　处：《中华危重病急救医学》2020年第5期625-631,共7页Chinese Critical Care Medicine

基　　金：四川省科技计划项目(2017FZ0058);四川省卫生健康委员会科研项目(17PJ474);四川省成都市科技惠民项目(2016-HM02-00025-SF)。

摘　　要：肺动脉高压(PAH)是一种以肺血管阻力和肺动脉压力进行性升高为特征,并最终导致右心衰竭的致死性心血管疾病。高迁移率族蛋白B1(HMGB1)是一种主要表达于细胞核内的DNA结合蛋白,因其多种细胞定位而具有多种相应功能。近年来研究显示,HMGB1在PAH患者肺部表达明显上调,其受体信号转导通路能够促发炎症反应及肺血管重构,从而诱导PAH发生,并且HMGB1及其受体信号转导通路中的多位点有望成为PAH治疗的新靶点。本文就PAH的炎症免疫机制、HMGB1的生物学特性及其在PAH发生发展中的主要作用进行综述,以期发现PAH治疗新途径。Pulmonary arterial hypertension(PAH)is a fatal cardiovascular disease characterized by progressively increases of pulmonary vascular resistance and pulmonary arterial pressure,and finally leading to right heart failure.High-mobility group B1(HMGB1)is a DNA-binding protein mainly expressed in the nucleus and has a variety of corresponding functions due to its diverse cellular localization.Recent studies have shown that HMGB1 is significantly up-regulated in the lungs of PAH patients,and its receptor signal transduction pathway promotes inflammatory response and pulmonary vascular remodeling to induce PAH.In addition,these multiple sites in HMGB1 and its receptor signal transduction pathway are expected to be the new targets for PAH therapy.In this paper,the inflammatory immune mechanism of PAH,the biological characteristics of HMGB1 and its main role in the occurrence and development of PAH are reviewed in order to discover the new treatment of PAH.

关 键 词：肺动脉高压 高迁移率族蛋白B1 损伤相关分子模式 Toll样受体 模式识别受体 晚期糖基化终末产物受体 炎症反应 肺动脉平滑肌细胞 肺血管重构 

分 类 号：R544.1[医药卫生—心血管疾病]